Answers are grounded in this paper and cite their sources.
Examines how Vimentin influences lipid accumulation in insulin-resistant mice, suggesting new treatment pathways.
Insulin resistance is known for promoting lipid accumulation in hepatocytes mainly by enhancing hepatic de novo lipogenesis (DNL), thereby playing a role in the development and progression of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Nonetheless, the paradox persists that hepatocytes sustain enhanced DNL activity despite compromised insulin signaling. The molecular mechanisms that sustain this lipogenic drive in the presence of insulin resistance remain inadequately elucidated, highlighting a significant deficiency in our comprehension of MAFLD aetiology. In this study, we observed that a high-fat diet (HFD) increases the expression and release of Vimentin from Kupffer Cells (KCs), which, in turn, cross-talks with the hepatocytes' IGF1 receptor (IGF-1R) to sequester LKB1 in the nucleus and repress AMPK activation. Serum vimentin levels were elevated in patients with MAFLD and the HFD-induced MAFLD mouse model. Interestingly, both KC depletion and the Vimentin knockdown attenuated intrahepatic fat accumulation. Moreover, supplementation of recombinant Vimentin in KC-depleted HFD mice resulted in increased intrahepatic lipid accumulation, suggesting a plausible role of Vimentin in the pathophysiology of MAFLD. Mechanistically, HFD increased Vimentin expression. Upon secretion from KCs, Vimentin interacts with IGF-1R of the hepatocytes, leading to reduced hepatic AMPK activation and enhanced DNL. Thus, the study shows that obesity promotes hepatic DNL in the insulin-resistant state via Vimentin, a hitherto unknown organokine.
No takes yet. Share an insight, caveat, or question.
Rawat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: